DMD: Eteplirsen-Treated Boys Show Continued Stability at 120 Weeks

Boys with Duchenne muscular dystrophy (DMD) participating in a phase 2b extension trial of the experimental exon-skipping drug eteplirsen showed continued stabilization of walking distance at 120 weeks. Sarepta Therapeutics, developer of eteplirsen, announced the findings in a Jan. 15, 2014, press release.

A webcast of Sarepta’s presentation at the J.P Morgan Healthcare Conference will be available on the Sarepta site today at 4:30 p.m. Pacific (7:30 p.m. Eastern).

Be sure to check back tomorrow for a recap of Sarepta's presentation at quest.mda.org and mda.org.

Disease: 
Link: 
GUID: 
22 926
Time Stamp: 
0
Thumbnail: 
http://quest.mda.org/sites/default/files/imagecache/mda_org_100x75/medPharmaResearch_700x450.jpg
Node Type: 
Quest News